Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jan 11

PMID 38201469

Authors

Martina Canichella

Matteo Molica

Carla Mazzone

Paolo de Fabritiis

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptors (CAR)-T-cell therapy represents the most important innovation in onco-hematology in recent years. The progress achieved in the management of complications and the latest generations of CAR-T-cells have made it possible to anticipate in second-line the indication of this type of treatment in large B-cell lymphoma. While some types of B-cell lymphomas and B-cell acute lymphoid leukemia have shown extremely promising results, the same cannot be said for myeloid leukemias-in particular, acute myeloid leukemia (AML), which would require innovative therapies more than any other blood disease. The heterogeneities of AML cells and the immunological complexity of the interactions between the bone marrow microenvironment and leukemia cells have been found to be major obstacles to the clinical development of CAR-T in AML. In this review, we report on the main results obtained in AML clinical trials, the preclinical studies testing potential CAR-T constructs, and future perspectives.

Citing Articles

Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.

Zhou D, Zhu X, Xiao Y Cancer Med. 2024; 13(11):e7375.

PMID: 38864474 PMC: 11167615. DOI: 10.1002/cam4.7375.

References

Wu G, Guo S, Luo Q, Wang X, Deng W, Ouyang G . Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. Front Immunol. 2023; 14:1093750. PMC: 9950117. DOI: 10.3389/fimmu.2023.1093750. View

Baumeister S, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi J . Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2018; 7(1):100-112. PMC: 7814996. DOI: 10.1158/2326-6066.CIR-18-0307. View

Richards R, Zhao F, Freitas K, Parker K, Xu P, Fan A . NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity. Blood Cancer Discov. 2021; 2(6):648-665. PMC: 8580619. DOI: 10.1158/2643-3230.BCD-20-0208. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius J, Sievers S . Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. Mol Ther. 2017; 25(11):2452-2465. PMC: 5675490. DOI: 10.1016/j.ymthe.2017.07.013. View

Nguyen D, Ball E, Varki A . Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs. Exp Hematol. 2006; 34(6):728-35. DOI: 10.1016/j.exphem.2006.03.003. View

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

Depil S, Duchateau P, Grupp S, Mufti G, Poirot L . 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020; 19(3):185-199. DOI: 10.1038/s41573-019-0051-2. View

Cordoba S, Onuoha S, Thomas S, Pignataro D, Hough R, Ghorashian S . CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med. 2021; 27(10):1797-1805. PMC: 8516648. DOI: 10.1038/s41591-021-01497-1. View

10.

van Rhenen A, van Dongen G, Kelder A, Rombouts E, Feller N, Moshaver B . The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007; 110(7):2659-66. DOI: 10.1182/blood-2007-03-083048. View

11.

Liu Y, Wang S, Schubert M, Lauk A, Yao H, Blank M . CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer. 2021; 150(7):1141-1155. DOI: 10.1002/ijc.33865. View

12.

Fried S, Avigdor A, Bielorai B, Meir A, Besser M, Schachter J . Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019; 54(10):1643-1650. DOI: 10.1038/s41409-019-0487-3. View

13.

Garrity D, Call M, Feng J, Wucherpfennig K . The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci U S A. 2005; 102(21):7641-6. PMC: 1140444. DOI: 10.1073/pnas.0502439102. View

14.

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

15.

Majzner R, Mackall C . Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov. 2018; 8(10):1219-1226. DOI: 10.1158/2159-8290.CD-18-0442. View

16.

John S, Chen H, Deng M, Gui X, Wu G, Chen W . A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. Mol Ther. 2018; 26(10):2487-2495. PMC: 6171100. DOI: 10.1016/j.ymthe.2018.08.001. View

17.

Cheadle E, Gornall H, Baldan V, Hanson V, Hawkins R, Gilham D . CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev. 2013; 257(1):91-106. DOI: 10.1111/imr.12126. View

18.

Arcangeli S, Rotiroti M, Bardelli M, Simonelli L, Magnani C, Biondi A . Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia. Mol Ther. 2017; 25(8):1933-1945. PMC: 5542631. DOI: 10.1016/j.ymthe.2017.04.017. View

19.

Dotti G, Gottschalk S, Savoldo B, Brenner M . Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2013; 257(1):107-26. PMC: 3874724. DOI: 10.1111/imr.12131. View

20.

De Kouchkovsky I, Abdul-Hay M . 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J. 2016; 6(7):e441. PMC: 5030376. DOI: 10.1038/bcj.2016.50. View